TSND-201

Phase 3Small molecule

TTranscend Therapeutics

TSND-201 is one of 55 small molecule programs targeting Post-Traumatic Stress Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post-Traumatic Stress DisorderEnrolling by invitation

Post-Traumatic Stress DisorderPhase 3

Enrolling by invitation

Competition

Competitive Landscape

61 competitors in Post-Traumatic Stress Disorder

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

5 2

Minipress

Pfizer

Approved

4 3

Epidiolex

Jazz Pharmaceuticals

Approved

2 4

Ritalin

Novartis

Approved

1 5

Namenda

AbbVie

Approved

1 6

Marinol

Jazz Pharmaceuticals

Approved

1 7

Revia

Teva

Approved

1 8

Zoloft

VViatris Specialty LLC

Approved

7 9

Inderal

WWyeth-Lederle Vaccines

Approved

5 10

Paxil

SSebela Pharmaceuticals Development LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Post-Traumatic Stress Disorder

NCT07456696

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder2 trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

Recruiting·TTranscend Therapeutics·Phase 3·NCT07456696·300 enrolled

A Phase 3 Open-Label Extension Study to Assess the Long-term Safety and Efficacy of TSND-201 for the Treatment of PTSD

Enrolling by invitation·TTranscend Therapeutics·Phase 3·NCT07670702·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TSND-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TSND-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TSND-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Transcend Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTranscend Therapeutics

TSND-201

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Post-Traumatic Stress Disorder2 trials

References

Drug Info

Quick Facts

Related News